{"id":745505,"date":"2017-08-29T01:31:00","date_gmt":"2017-08-29T01:31:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\/"},"modified":"2025-11-07T01:26:19","modified_gmt":"2025-11-07T06:26:19","slug":"merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\/","title":{"rendered":"Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease"},"content":{"rendered":"<p class=\"bwalignc\">       Results Published in The New England Journal of Medicine and        Presented at the European Society of Cardiology Congress     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, and<br \/>\n      researchers in the Clinical Trial Service Unit at the University of<br \/>\n      Oxford, today announced the publication and presentation of results from<br \/>\n      the REVEAL (Randomized EValuation of the Effects of Anacetrapib through<br \/>\n      Lipid modification) outcomes study of anacetrapib, Merck\u2019s<br \/>\n      investigational cholesteryl ester transfer protein (CETP) inhibitor. In<br \/>\n      the study of 30,449 patients with atherosclerotic vascular disease<br \/>\n      receiving LDL-C lowering treatment with atorvastatin, anacetrapib<br \/>\n      significantly reduced the risk of major coronary events (composite of<br \/>\n      coronary death, myocardial infarction or coronary revascularization) by<br \/>\n      9 percent relative to placebo (10.8% vs. 11.8%, respectively; P=0.004).<br \/>\n      The safety of anacetrapib was generally consistent with data from<br \/>\n      earlier trials of the drug. However, a sub-study also showed that<br \/>\n      anacetrapib accumulates in adipose tissue with prolonged dosing. Merck<br \/>\n      is reviewing the results of the trial with external experts and will<br \/>\n      consider whether to file new drug applications with the U.S. Food and<br \/>\n      Drug Administration (FDA) and other regulatory agencies.\n    <\/p>\n<p>\n      The results of REVEAL were presented today by Dr. Martin Landray of the<br \/>\n      University of Oxford, the trial\u2019s co-principal investigator, during a<br \/>\n      late-breaking clinical trials session at the European Society of<br \/>\n      Cardiology Congress, and simultaneously published in the online edition<br \/>\n      of <i>The New England Journal of Medicine<\/i>. REVEAL was designed and<br \/>\n      independently conducted by investigators at the Clinical Trial Service<br \/>\n      Unit at the University of Oxford, the trial\u2019s regulatory sponsor, in<br \/>\n      collaboration with the TIMI Study Group based at Brigham and Women\u2019s<br \/>\n      Hospital in Boston and Merck. Merck provided funding for REVEAL.\n    <\/p>\n<p>\n      \u201cDespite treatment advances in recent years, patients with<br \/>\n      cardiovascular disease remain at risk for cardiovascular events. We are<br \/>\n      pleased that adding anacetrapib to statin therapy resulted in a further<br \/>\n      reduction of major coronary events in REVEAL,\u201d said Dr. Roy Baynes,<br \/>\n      senior vice president, head of clinical development, and chief medical<br \/>\n      officer, Merck Research Laboratories. \u201cThis trial helps to advance our<br \/>\n      understanding of the effects of anacetrapib on cardiovascular risk, and<br \/>\n      we are grateful to the study leaders at Oxford, TIMI, the many<br \/>\n      investigators, and the thousands of patients who participated in this<br \/>\n      study for their efforts.\u201d\n    <\/p>\n<p>\n      In the randomized, double-blind, placebo-controlled study, 30,449 adults<br \/>\n      with atherosclerotic vascular disease on study-mandated intensive<br \/>\n      atorvastatin therapy (mean baseline LDL cholesterol level 61 mg\/dL [1.58<br \/>\n      mmol\/L], non-HDL cholesterol 92 mg\/dL [2.38 mmol\/L], and HDL cholesterol<br \/>\n      40 mg\/dL [1.03 mg\/dL]) were randomly assigned to receive either<br \/>\n      anacetrapib 100 mg once daily or matching placebo. The primary<br \/>\n      assessment was an intention-to-treat comparison among all randomized<br \/>\n      participants of the effect of anacetrapib on the composite of major<br \/>\n      coronary events, defined as the first occurrence of coronary death,<br \/>\n      myocardial infarction, or coronary revascularization.\n    <\/p>\n<p>\n      Compared with placebo, the addition of anacetrapib further reduced the<br \/>\n      mean level of non-HDL cholesterol by 17 mg\/dL (0.44 mmol\/L,18%) and<br \/>\n      increased HDL cholesterol level by 43 mg\/dL (1.12 mmol\/L, 104%) at the<br \/>\n      study midpoint. During median follow-up of 4.1 years, a 9 percent<br \/>\n      relative reduction in the risk major coronary events was observed among<br \/>\n      those receiving anacetrapib compared to placebo (1640 events [10.8%] vs.<br \/>\n      1803 events [11.8%]; rate ratio 0.91; 95% CI 0.85 to 0.97; P=0.004). The<br \/>\n      benefit was similar across multiple pre-specified subgroups.\n    <\/p>\n<p>\n      The difference in the key secondary composite outcome of major<br \/>\n      atherosclerotic events (myocardial infarction, coronary death or<br \/>\n      presumed ischemic stroke) did not reach statistical significance (rate<br \/>\n      ratio, 0.93; 95% CI, 0.86 to 1.00; P=0.052), possibly due to a lack of<br \/>\n      observed benefit of anacetrapib on presumed ischemic stroke. There were<br \/>\n      no statistically significant differences in cause-specific mortality,<br \/>\n      cancer, or other serious adverse events. Anacetrapib produced small<br \/>\n      increases in systolic and diastolic blood pressures of 0.7 mmHg and 0.3<br \/>\n      mmHg, respectively; there was no statistically significant increase of<br \/>\n      serious adverse events attributed to hypertension. Compared to those<br \/>\n      receiving placebo, more patients in the anacetrapib group developed an<br \/>\n      estimated glomerular filtration rate of less than 60 ml\/min\/1.73m<sup>2<\/sup><br \/>\n      by the end of the study (11.5% vs. 10.6%; P=0.04); there was no<br \/>\n      statistically significant impact on the development of albuminuria or<br \/>\n      serious adverse events attributed to renal failure.\n    <\/p>\n<p>\n      Details on the REVEAL study design are available at clinicaltrials.gov: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT01252953&amp;esheet=51675005&amp;newsitemid=20170828006014&amp;lan=en-US&amp;anchor=https%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT01252953&amp;index=1&amp;md5=55d0c904a2e056cb17680527e2f0323f\" rel=\"nofollow\">https:\/\/clinicaltrials.gov\/show\/NCT01252953<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51675005&amp;newsitemid=20170828006014&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=50411580795118d93d614ffad5ad50b1\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51675005&amp;newsitemid=20170828006014&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=698b4df07a487f44af22325035af7910\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51675005&amp;newsitemid=20170828006014&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=c114e8cbe97437c633081d507d35660e\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51675005&amp;newsitemid=20170828006014&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=4ef8880020d54b7d9df8a70738aeb914\" rel=\"nofollow\">Instagram<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51675005&amp;newsitemid=20170828006014&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=c87f07d2e8b9fa835c5601e3b8650300\" rel=\"nofollow\">YouTube<\/a>&nbsp;and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51675005&amp;newsitemid=20170828006014&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=ed98e98e04f4955c2d8cea0cdfab84e5\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51675005&amp;newsitemid=20170828006014&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=ecb9d33928b9add40713341ed309d136\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170828006014r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, +1 (267) 305-3558<br \/>or<br \/>Kate        Prout, +1 (267) 980-7601<br \/>or<br \/>Investor:<br \/>Amy Klug, +1 (908)        740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Results Published in The New England Journal of Medicine and Presented at the European Society of Cardiology Congress Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, and researchers in the Clinical Trial Service Unit at the University of Oxford, today announced the publication and presentation of results from the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib, Merck\u2019s investigational cholesteryl ester transfer protein (CETP) inhibitor. In the study of 30,449 patients with atherosclerotic vascular disease receiving LDL-C lowering treatment with atorvastatin, anacetrapib significantly reduced the risk of major coronary events (composite of coronary death, myocardial infarction or coronary revascularization) by 9 percent relative to placebo (10.8% vs. 11.8%, respectively; P=0.004). The safety of anacetrapib was generally consistent with data from earlier trials of the drug. However, a sub-study also showed<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745505","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Results Published in The New England Journal of Medicine and Presented at the European Society of Cardiology Congress Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, and researchers in the Clinical Trial Service Unit at the University of Oxford, today announced the publication and presentation of results from the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib, Merck\u2019s investigational cholesteryl ester transfer protein (CETP) inhibitor. In the study of 30,449 patients with atherosclerotic vascular disease receiving LDL-C lowering treatment with atorvastatin, anacetrapib significantly reduced the risk of major coronary events (composite of coronary death, myocardial infarction or coronary revascularization) by 9 percent relative to placebo (10.8% vs. 11.8%, respectively; P=0.004). The safety of anacetrapib was generally consistent with data from earlier trials of the drug. However, a sub-study also showed\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\\\/\",\"name\":\"Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-08-29T01:31:00+00:00\",\"dateModified\":\"2025-11-07T06:26:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease - Merck.com","og_description":"Results Published in The New England Journal of Medicine and Presented at the European Society of Cardiology Congress Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, and researchers in the Clinical Trial Service Unit at the University of Oxford, today announced the publication and presentation of results from the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib, Merck\u2019s investigational cholesteryl ester transfer protein (CETP) inhibitor. In the study of 30,449 patients with atherosclerotic vascular disease receiving LDL-C lowering treatment with atorvastatin, anacetrapib significantly reduced the risk of major coronary events (composite of coronary death, myocardial infarction or coronary revascularization) by 9 percent relative to placebo (10.8% vs. 11.8%, respectively; P=0.004). The safety of anacetrapib was generally consistent with data from earlier trials of the drug. However, a sub-study also showed","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:19+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\/","name":"Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-08-29T01:31:00+00:00","dateModified":"2025-11-07T06:26:19+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-investigational-medicine-for-cardiovascular-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"371721d1-783f-415d-9352-4be1d5a4fc3b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Results-of-REVEAL-Outcomes-Study-of-Anacetrapib-Investigational-Medicine-for-Cardiovascular-Disease-2017.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745505\/revisions"}],"predecessor-version":[{"id":3674861,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745505\/revisions\/3674861"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745505"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}